EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting capacity, safety and efficacy of engineered extracellular vesicles delivered by transdermal microneedles to treat plasmacytoma in mice

Yulin Cao iD, Xuan Hu, Di Wu, Yuxuan Jiang, Yali Yu, Shan Wang, Wenlan Chen, Yaoying Long, Liuyue Xu, Jiao Qu, Bianlei Yang, Blal Chakhabi und 5 weitere

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Yulin Cao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Plasmacytoma, Drug Delivery Systems. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Hubei Innovation Group Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Engineered extracellular vesicles (EVs) are emerging as a highly potential platform for targeted drug delivery in cancer therapy. Although intravenous injection is commonly used in EV treatment, there is growing interest in using microneedles (MNs) for transdermal EV delivery; however, comprehensive studies comparing the tissue distribution, safety and antitumour efficacy of these two approaches for delivering engineered EVs remain scarce.

Methods

We used EVs derived from umbilical cord mesenchymal stem cells, modified with phospholipid‒polyethylene glycol‒N‐hydroxysuccinimide and conjugated with CD38 peptides (CD38‐EVs), to target myeloma cells that highly express CD38 antigen, and tested their safety and antitumour efficacy in mice with subcutaneous plasmacytoma, administrated via dissolvable transdermal MNs or intravenous injection. Flow cytometry, immunofluorescence and fluorescence molecular projection imaging analysis were employed to evaluate the distribution of CD38‐EVs at the cellular level and within living systems. Additionally, histopathological analysis and biochemical analyses were conducted to assess the antitumour effects and safety of CD38‐EVs loaded with doxorubicin (CD38‐EVs‐Dox).

Results

Compared to standard EVs, CD38‐EVs exhibited enhanced uptake by CD38 high tumour cells and reduced uptake by CD38‐negative non‐tumour cells in vitro. In plasmacytoma NOD/SCID mouse models, CD38‐EVs encapsulated within MNs (CD38‐EVs MNs ) effectively targeted the tumour cells much more than the standard EVs encapsulated within MNs (EVs MNs ) and CD38‐EVs intravenously administrated (CD38‐EVs i.v ), with reduced distribution to the lungs and spleen. Additionally, CD38‐EVs‐Dox induced significantly greater cytotoxicity against the tumour cells than EVs‐Dox in vitro, and CD38‐EVs‐Dox MNs significantly reduced tumour burden compared to both EVs‐Dox MNs and CD38‐EVs‐Dox i.v , while maintaining favourable safety profiles.

Conclusions

CD38‐EVs‐Dox MNs have superior efficacy and safety in treating plasmacytoma mice, compared to CD38‐EVs‐Dox i.v , providing novel insights into the potential of MNs as a platform for delivering targeted engineered EVs in tumour therapy. Highlights Enhanced tumor targeting : CD38‐modified EVs (CD38‐EVs) showed increased uptake by CD38high tumor cells while reducing uptake by CD38‐negative non‐tumor cells. Optimized delivery : MN‐loaded CD38‐EVs targeted tumors more effectively than MN‐loaded EVs and intravenously injected CD38‐EVs, with lower lung and spleen accumulation. Superior antitumor efficacy : MN‐delivered CD38‐EVs‐Dox significantly suppressed tumor growth, outperforming intravenous CD38‐EVs‐Dox and MN‐delivered EVs‐Dox.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesPlasmacytomaDrug Delivery SystemsAnimalsMiceAdministration, CutaneousNeedlesDoxorubicinHumansDisease Models, Animal

Stichwörter der Autor:innen

CD38 peptidedrug delivery systemextracellular vesiclesintravenous administrationmicroneedlesplasmacytoma

Substanzen

Doxorubicin

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan, China.
  • MoE Key Laboratory for Biomedical Photonics, Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Yulin Cao, Qiubai Li

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Hubei Innovation Group Foundation
  • Open Project Program of Wuhan National Laboratory for Optoelectronics

Zitieren

APA

Cao, Y., Hu, X., Wu, D., Jiang, Y., Yu, Y., Wang, S., Chen, W., Long, Y., Xu, L., Qu, J., Yang, B., Chakhabi, B., Wang, H., Deng, Y., Chen, L., Chen, Z., & Li, Q. (2025). Targeting capacity, safety and efficacy of engineered extracellular vesicles delivered by transdermal microneedles to treat plasmacytoma in mice. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70327

Vancouver

Cao Y, Hu X, Wu D, Jiang Y, Yu Y, Wang S, et al. Targeting capacity, safety and efficacy of engineered extracellular vesicles delivered by transdermal microneedles to treat plasmacytoma in mice. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70327

BibTeX
@article{Cao2025,
  author = {Cao, Yulin and Hu, Xuan and Wu, Di and Jiang, Yuxuan and Yu, Yali and Wang, Shan and Chen, Wenlan and Long, Yaoying and Xu, Liuyue and Qu, Jiao and Yang, Bianlei and Chakhabi, Blal and Wang, Hongxiang and Deng, Yong and Chen, Lei and Chen, Zhichao and Li, Qiubai},
  title = {Targeting capacity, safety and efficacy of engineered extracellular vesicles delivered by transdermal microneedles to treat plasmacytoma in mice},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70327}
}
Kostenlos starten →